{"name":"ParaPRO LLC","slug":"parapro-llc","ticker":"","exchange":"","domain":"","description":"ParaPRO LLC is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for dermatological conditions. With a pipeline of nine drugs, the company is advancing several candidates through clinical trials, including a phase 3 program for Permethrin 1%.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Permethrin 1%","genericName":"Permethrin 1%","slug":"permethrin-1","indication":"Treatment of head lice and scabies","status":"phase_3"},{"name":"spinosad topical suspension, 0.9%","genericName":"spinosad topical suspension, 0.9%","slug":"spinosad-topical-suspension-0-9","indication":"Control of fire ants, harvester ants, and other listed pests in lawns and turf","status":"phase_3"}]}],"pipeline":[{"name":"Permethrin 1%","genericName":"Permethrin 1%","slug":"permethrin-1","phase":"phase_3","mechanism":"Permethrin 1% acts as an acaricide and insecticide by disrupting the nervous system of insects and arachnids.","indications":["Treatment of head lice and scabies"],"catalyst":""},{"name":"spinosad topical suspension, 0.9%","genericName":"spinosad topical suspension, 0.9%","slug":"spinosad-topical-suspension-0-9","phase":"phase_3","mechanism":"Spinosad topical suspension works by activating nicotinic acetylcholine receptors in the insect nervous system, ultimately leading to the death of the insect.","indications":["Control of fire ants, harvester ants, and other listed pests in lawns and turf"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxNaU9iSm9sbHpLbzZwOVhZWDNtalMyYlE3WG5YTnUyaERuWHZxQ3pXblAtQ25pbVp6VVFSUGZPWG8wVmdwZzd4am5BWHZtcXBLOXFQNkRScENhRnRQWU5GVW1Sdi0yOURqNndKblRCQ05XWGh5YXQ1S2UzLXJWekN5STBxbldoWndXcUJZWGxaZXI3ZFZQWjU1alZkZi1XbWpaWnlVUm5ZcU1hWkhTLW9hY2lyOUZFNGwtcjUyS0RoUGpGZGVWMTBZM0QxTnQ3Q1NSQS02UF9nbHFDWjdPenpWTUpxOGRoSUNUNEIwQVlRQnR0NDZmNVg3c0ZvZGdJVmc5bVFDXzBtajBUN3RxZHBuSkQ5V1piZmNEaUFqWW8xYmdsbThLNXk3d0VKZi1oUQ?oc=5","date":"2022-10-07","type":"pipeline","source":"PR Newswire","summary":"PARAPRO INTRODUCES THE FIRST AI-BASED INTERACTIVE MEDICAL EDUCATION PLATFORM AT THE AMERICAN ACADEMY OF PEDIATRICS NATIONAL CONFERENCE AND EXHIBITION - PR Newswire","headline":"PARAPRO INTRODUCES THE FIRST AI-BASED INTERACTIVE MEDICAL EDUCATION PLATFORM AT THE AMERICAN ACADEMY OF PEDIATRICS NATIO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxPM09vNHNFZUlRdFNMMU91TjFUQXh0SDZjejA4Y1AwRDY0YzhoQUpJRFFyRlpzRFJuanNmR052eU11MmpYdnp5UDVlLXZKdUt4MW4ybldmQjhzRXFWTlFnVDRnVnpNazFIRWk5MWwySDdzZHpoemRVeXF1OWFrY2tJaEItUEtzSnNQV0pBazlVX2JleWlteHRVRThhWWZGOXFzb3QwZnRFT2doSzh4blBmY1Jmc0F2NW9qdEFWcHB5T1pVb2FRNHhHaHk5NWpCRHF0?oc=5","date":"2021-08-02","type":"pipeline","source":"BioSpace","summary":"ParaPRO Announces Availability of Natroba™ (spinosad) Topical Suspension, 0.9% for the Treatment of Scabies - BioSpace","headline":"ParaPRO Announces Availability of Natroba™ (spinosad) Topical Suspension, 0.9% for the Treatment of Scabies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxPSUllSXNtUndPWG9XWlUzcXp3RWM0Sm53MWp4N2NQdEdNQ3FRWVhnWTVCOE9VaE5mQkhUZUh4LUV2T0FyclNIUG9hRjVTakxiekhEZjc4bXFYeG4yY1FsbXFyQXZJMzZGMHJHTVdPUDZHTVVZRThibDhTNm1jVk4xeUlqVjdoTjdCYzdnLVhGQXdQbV8waWMwbzgwc0tHQjFhVE13eFZQM2JYSDJRZkl2NXZHZ09NQ0xTN3M4dHZVcGhsbmpzWTlMRkJaVWZlMkRBcHBERFBUekNxcHVGeUZybFJoOUtzMklkWUlDQlVn?oc=5","date":"2017-09-19","type":"pipeline","source":"European Medical Journal","summary":"RedHill Biopharma Initiates Promotion of Esomeprazole Strontium Delayed-Release Capsules 49.3 mg in the U.S. - European Medical Journal","headline":"RedHill Biopharma Initiates Promotion of Esomeprazole Strontium Delayed-Release Capsules 49.3 mg in the U.S.","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}